UA81251C2 - Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method - Google Patents
Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method Download PDFInfo
- Publication number
- UA81251C2 UA81251C2 UAA200500168A UA2005000168A UA81251C2 UA 81251 C2 UA81251 C2 UA 81251C2 UA A200500168 A UAA200500168 A UA A200500168A UA 2005000168 A UA2005000168 A UA 2005000168A UA 81251 C2 UA81251 C2 UA 81251C2
- Authority
- UA
- Ukraine
- Prior art keywords
- recombinant
- fsh
- substance
- ganirelix
- dose
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 title claims abstract description 10
- 238000007920 subcutaneous administration Methods 0.000 claims abstract description 44
- 108700032141 ganirelix Proteins 0.000 claims abstract description 22
- 229960003794 ganirelix Drugs 0.000 claims abstract description 22
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 claims abstract description 22
- 230000002028 premature Effects 0.000 claims abstract description 22
- 230000021121 meiosis Effects 0.000 claims abstract description 15
- 210000002700 urine Anatomy 0.000 claims abstract description 11
- 230000007812 deficiency Effects 0.000 claims abstract description 9
- 238000011260 co-administration Methods 0.000 claims abstract description 7
- 208000024891 symptom Diseases 0.000 claims abstract description 6
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 103
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 103
- 229940040129 luteinizing hormone Drugs 0.000 claims description 103
- 108700008462 cetrorelix Proteins 0.000 claims description 23
- 229960003230 cetrorelix Drugs 0.000 claims description 23
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims description 23
- 230000002485 urinary effect Effects 0.000 claims description 18
- 230000029849 luteinization Effects 0.000 claims description 14
- 230000037396 body weight Effects 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 210000001161 mammalian embryo Anatomy 0.000 claims description 10
- 230000018109 developmental process Effects 0.000 claims description 6
- 230000005906 menstruation Effects 0.000 claims description 6
- 210000002394 ovarian follicle Anatomy 0.000 claims description 6
- 235000013601 eggs Nutrition 0.000 claims description 5
- 230000004720 fertilization Effects 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 210000004291 uterus Anatomy 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 101100120663 Drosophila melanogaster fs(1)h gene Proteins 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 80
- 239000005557 antagonist Substances 0.000 abstract description 42
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 abstract description 40
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 abstract description 40
- 229940028334 follicle stimulating hormone Drugs 0.000 abstract description 40
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract description 13
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract description 13
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 abstract description 13
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract description 12
- 230000003054 hormonal effect Effects 0.000 abstract description 5
- 239000002474 gonadorelin antagonist Substances 0.000 abstract description 2
- 229940088597 hormone Drugs 0.000 abstract description 2
- 239000005556 hormone Substances 0.000 abstract description 2
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 abstract 2
- 230000008217 follicular development Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000001592 luteinising effect Effects 0.000 abstract 1
- 238000002513 implantation Methods 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000003070 Statistical process control Methods 0.000 description 10
- 230000035935 pregnancy Effects 0.000 description 10
- 239000000556 agonist Substances 0.000 description 9
- 210000000287 oocyte Anatomy 0.000 description 9
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 102000006771 Gonadotropins Human genes 0.000 description 5
- 108010086677 Gonadotropins Proteins 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 239000002622 gonadotropin Substances 0.000 description 5
- 229940094892 gonadotropins Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 4
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 4
- 206010062767 Hypophysitis Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000016087 ovulation Effects 0.000 description 4
- 210000003635 pituitary gland Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004246 corpus luteum Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229940015047 chorionic gonadotropin Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002503 granulosa cell Anatomy 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000009027 insemination Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- PYTMYKVIJXPNBD-OQKDUQJOSA-N 2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 PYTMYKVIJXPNBD-OQKDUQJOSA-N 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 101000818510 Homo sapiens Zinc-activated ligand-gated ion channel Proteins 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 102100021143 Zinc-activated ligand-gated ion channel Human genes 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940046989 clomiphene citrate Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 231100000547 follicle rupture Toxicity 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- -1 heterocyclic low molecular weight compounds Chemical class 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 229960003454 tamoxifen citrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02077221 | 2002-06-07 | ||
| PCT/NL2003/000370 WO2003103770A2 (en) | 2002-06-07 | 2003-06-06 | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA81251C2 true UA81251C2 (en) | 2007-12-25 |
Family
ID=29724462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200500168A UA81251C2 (en) | 2002-06-07 | 2003-06-06 | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7815912B2 (no) |
| EP (1) | EP1511537B1 (no) |
| JP (1) | JP2005530818A (no) |
| KR (1) | KR20050058285A (no) |
| CN (1) | CN1684737A (no) |
| AU (1) | AU2003274929B2 (no) |
| BR (1) | BR0305033A (no) |
| CA (1) | CA2488719A1 (no) |
| EA (1) | EA009371B1 (no) |
| ES (1) | ES2399962T3 (no) |
| IL (1) | IL165522A0 (no) |
| IS (1) | IS7586A (no) |
| ME (1) | MEP39308A (no) |
| MX (1) | MXPA04012246A (no) |
| NO (1) | NO20045304L (no) |
| NZ (1) | NZ536984A (no) |
| PL (1) | PL373991A1 (no) |
| RS (1) | RS105004A (no) |
| UA (1) | UA81251C2 (no) |
| WO (1) | WO2003103770A2 (no) |
| ZA (1) | ZA200409857B (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101583363B (zh) * | 2007-01-08 | 2013-08-21 | 潘塔希生物科学股份有限公司 | 治疗或预防雌性哺乳动物不育症的方法和此类方法中使用的药物试剂盒 |
| KR20140053991A (ko) * | 2011-07-18 | 2014-05-08 | 아츠 바이올로직스 에이/에스 | 장기간 작용하는 황체 형성 호르몬 (ｌｈ) 화합물 |
| US9282995B2 (en) * | 2011-12-22 | 2016-03-15 | Previvo Genetics, Llc | Recovery and processing of human embryos formed in vivo |
| US20150272622A1 (en) | 2011-12-22 | 2015-10-01 | Previvo Genetics, Llc | Recovery and processing of human embryos formed in vivo |
| US9216037B2 (en) | 2013-06-21 | 2015-12-22 | Previvo Genetics, Llc | Uterine lavage for embryo retrieval |
| MX2019000498A (es) | 2016-07-21 | 2019-09-16 | ObsEva SA | Regímenes de dosis de antagonista de oxitocina para promover la implantación embrionaria y prevenir abortos espontaneos. |
| WO2021043726A1 (en) | 2019-09-03 | 2021-03-11 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| EP4103750A1 (en) | 2020-02-10 | 2022-12-21 | ObsEva S.A. | Biomarkers for oxytocin receptor antagonist therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0788799A3 (en) * | 1996-02-07 | 1998-10-21 | ASTA Medica Aktiengesellschaft | LHRH-Antagonists in the treatment of fertility disorders |
| CN1199642A (zh) * | 1997-05-16 | 1998-11-25 | Asta药物股份公司 | 治疗不育症的lhrh－拮抗剂 |
| EP0994718B1 (en) * | 1997-06-20 | 2005-08-17 | Akzo Nobel N.V. | Gonadotropin releasing hormone antagonist |
| AU752415B2 (en) | 1998-04-23 | 2002-09-19 | Zentaris Ivf Gmbh | Method for the treatment of fertility disorders |
| BR0008468A (pt) * | 1999-02-24 | 2002-02-05 | Novo Nordisk As | Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos |
| CA2341974A1 (en) | 1999-06-23 | 2001-01-04 | Akzo Nobel Nv | Gonadotropin releasing hormone antagonist |
| US20030092628A1 (en) * | 1999-06-23 | 2003-05-15 | De Greef Henrik Johan Matthieu Maria | Gonadotropin releasing hormone antagonist |
| MEP38808A (en) * | 2001-09-12 | 2011-02-10 | Merck Serono Sa | Use of lh in controlled ovarian hyperstimulation |
| EP1455831B1 (en) | 2001-12-21 | 2007-10-31 | Pantarhei Bioscience B.V. | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method |
-
2003
- 2003-06-06 BR BR0305033-5A patent/BR0305033A/pt not_active IP Right Cessation
- 2003-06-06 CN CNA038183900A patent/CN1684737A/zh active Pending
- 2003-06-06 NZ NZ536984A patent/NZ536984A/en unknown
- 2003-06-06 MX MXPA04012246A patent/MXPA04012246A/es unknown
- 2003-06-06 US US10/517,028 patent/US7815912B2/en not_active Expired - Fee Related
- 2003-06-06 KR KR1020047019890A patent/KR20050058285A/ko not_active Application Discontinuation
- 2003-06-06 EA EA200401619A patent/EA009371B1/ru not_active IP Right Cessation
- 2003-06-06 UA UAA200500168A patent/UA81251C2/uk unknown
- 2003-06-06 CA CA002488719A patent/CA2488719A1/en not_active Abandoned
- 2003-06-06 AU AU2003274929A patent/AU2003274929B2/en not_active Ceased
- 2003-06-06 WO PCT/NL2003/000370 patent/WO2003103770A2/en active Application Filing
- 2003-06-06 JP JP2004510888A patent/JP2005530818A/ja active Pending
- 2003-06-06 ME MEP-393/08A patent/MEP39308A/xx unknown
- 2003-06-06 EP EP03741621A patent/EP1511537B1/en not_active Expired - Lifetime
- 2003-06-06 RS YUP-1050/04A patent/RS105004A/sr unknown
- 2003-06-06 ES ES03741621T patent/ES2399962T3/es not_active Expired - Lifetime
- 2003-06-06 PL PL03373991A patent/PL373991A1/xx not_active Application Discontinuation
-
2004
- 2004-12-02 IL IL16552204A patent/IL165522A0/xx unknown
- 2004-12-03 IS IS7586A patent/IS7586A/is unknown
- 2004-12-03 NO NO20045304A patent/NO20045304L/no not_active Application Discontinuation
- 2004-12-06 ZA ZA200409857A patent/ZA200409857B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200409857B (en) | 2006-02-22 |
| KR20050058285A (ko) | 2005-06-16 |
| EA200401619A1 (ru) | 2005-06-30 |
| BR0305033A (pt) | 2004-11-09 |
| AU2003274929A1 (en) | 2003-12-22 |
| WO2003103770A3 (en) | 2004-04-22 |
| MEP39308A (en) | 2011-02-10 |
| US20050235374A1 (en) | 2005-10-20 |
| EP1511537B1 (en) | 2012-11-21 |
| MXPA04012246A (es) | 2005-04-08 |
| CN1684737A (zh) | 2005-10-19 |
| PL373991A1 (en) | 2005-09-19 |
| EA009371B1 (ru) | 2007-12-28 |
| NZ536984A (en) | 2008-01-31 |
| ES2399962T3 (es) | 2013-04-04 |
| IL165522A0 (en) | 2006-01-15 |
| EP1511537A2 (en) | 2005-03-09 |
| CA2488719A1 (en) | 2003-12-18 |
| RS105004A (en) | 2007-02-05 |
| IS7586A (is) | 2004-12-03 |
| AU2003274929B2 (en) | 2008-04-10 |
| US7815912B2 (en) | 2010-10-19 |
| NO20045304L (no) | 2005-02-07 |
| JP2005530818A (ja) | 2005-10-13 |
| WO2003103770A2 (en) | 2003-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8236785B2 (en) | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method | |
| Huirne et al. | Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study | |
| US7405197B2 (en) | Use of hCG in controlled ovarian hyperstimulation | |
| UA81251C2 (en) | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method | |
| EP1455831B1 (en) | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method | |
| ES2356895T3 (es) | USO DE LA hCG Y LH EN LA HIPERESTIMULACIÓN OVÁRICA CONTROLADA. | |
| AU2002331939B2 (en) | Use of LH in controlled ovarian hyperstimulation | |
| ES2217113T5 (es) | Uso de fsh para tratar infertilidad. | |
| McCue | Hormone Therapy in Cycling Mares | |
| Nagori et al. | 6 Intrauterine Insemination | |
| Meridis et al. | Drugs in reproductive medicine | |
| Nagori et al. | Mild Ovarian Hyperstimulation and Intrauterine Insemination | |
| Huirne et al. | Effect of an OC pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study | |
| Ron-El R et al. | Characteristics of very short regimens |